Article Text

PDF
Anti-CD3 antibody visilizumab is not effective in patients with intravenous corticosteroid-refractory ulcerative colitis
  1. William J Sandborn1,
  2. Jean Frederic Colombel2,
  3. Matthew Frankel3,
  4. Daan Hommes4,
  5. James N Lowder3,
  6. Lloyd Mayer5,
  7. Scott Plevy6,
  8. Pieter Stokkers7,
  9. Simon Travis8,
  10. Gert Van Assche9,
  11. Daniel C Baumgart10,
  12. Stephan R Targan11
  1. 1Mayo Clinic, Rochester, Minnesota, USA
  2. 2Hopital Huriez-CIC Inserm CH et U de Lille, Lille, France
  3. 3Facet Biotech (previously PDL BioPharma), Redwood City, California, USA
  4. 4Leiden University Medical Center, Leiden, Netherlands
  5. 5Mount Sinai School of Medicine, New York, USA
  6. 6University of North Carolina Chapel Hill, Chapel Hill, North Carolina, USA
  7. 7Academic Medical Center, Amsterdam, Netherlands
  8. 8John Radcliffe Hospital, Oxford, UK
  9. 9University Hospital Gasthuisberg, Leuven, Belgium
  10. 10Charité Medical School of the Humboldt-University of Berlin, Berlin, Germany
  11. 11Cedars Sinai Medical Center, Los Angeles, California, USA
  1. Correspondence to Dr William J Sandborn, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA; sandborn.william{at}mayo.edu

Abstract

Background and aims Pilot studies with visilizumab, a humanised monoclonal antibody to CD3, suggest efficacy for corticosteroid-refractory ulcerative colitis (UC). A placebo-controlled trial was warranted.

Methods A randomised, double-blind, placebo-controlled study evaluated the efficacy of visilizumab induction treatment in 127 patients with severely active UC despite treatment with ≥5 days of intravenous corticosteroids. Patients received placebo or visilizumab 5 μg/kg intravenously on days 1 and 2. Corticosteroids were tapered according to disease activity. Patients were followed up for 90 days. The primary end point was induction of response at day 45. Secondary end points included remission and mucosal healing at day 45, symptomatic response at day 15 and colectomy.

Results Response at day 45 occurred in 55% of patients receiving visilizumab compared with 47% of those who received placebo (p=0.475). Remission at day 45 occurred in 8% of patients receiving visilizumab compared with 9% of those who received placebo (p=0.704). Mucosal healing at day 45 occurred in 29% of patients receiving visilizumab compared with 26% of those who received placebo (p=0.799). Symptomatic response at day 15 occurred in 82% of patients receiving visilizumab compared with 74% of those who received placebo (p=0.244). Colectomy was performed in 18% of patients receiving visilizumab compared with 7% of those who received placebo (p=0.130). Cardiac disorders and vascular disorders occurred more frequently in the patients who received visilizumab.

Conclusion Visilizumab at a dose of 5 μg/kg for two consecutive days was not effective for severe, corticosteroid-refractory UC and was associated with increased cardiac and vascular adverse events.

(Registered at http://www.clinicaltrials.govNCT00279422/).

  • Visilizumab
  • ulcerative colitis
  • CD3
  • T cells
  • randomised controlled study
  • inflammatory bowel disease
  • monoclonal antibody
  • induction therapy
  • antibody targeted therapy
  • clinical trials
  • steroid-sparing efficacy
View Full Text

Statistics from Altmetric.com

Footnotes

  • Funding Supported by a research grant from Facet Biotech (previously PDL BioPharma), Redwood City, California, USA.

  • Competing interests WS, JFC, DH, LM, ST, SRT, GV and STa have served as consultants and received research support from PDL BioPharma. PS and DCB have received research support from PDL BioPharma, MF and JNL are former employees of PDL BioPharma.

  • Ethics approval This multicentre study was conducted globally at 75 sites in 14 countries (Australia, Austria, Belgium, Canada, Czech Republic, France, Germany, Hungary, Israel, Netherlands, Norway, Slovakia, Ukraine, United States). The institutional review board or ethics committee at each site approved the protocol. All patients gave written informed consent.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles

  • Digest
    Emad El-Omar Severine Vermeire Alexander Gerbes